content_image/58476.jpg content_image/58475.jpg
above, as well as regulatory changes requiring a modification to our global compensation plan towards the end of 2002 , which was disconcerting to our distributor leaders in this market. 

Greater China.  The following table sets forth revenue for the Greater China region and its principal markets: 

<img src='content_image/58476.jpg'>

Revenue in Greater China increased primarily as a result of the expansion of operations in China. Foreign currency fluctuations from 2002  to 2003  did not have a notable impact on this region. Revenue in China was $ 38 . 5  million in 2003 , following our expansion of retail operations and the introduction of Nu Skin branded products in China in January 2003 . On a sequential basis, revenue in China increased 67 % from the third quarter to the fourth quarter. This growth is attrib- uted to an increased number of preferred customers and employed sales representatives in China. The success of our prod- uct launches and product promotions as well as our employment opportunities provide an attraction to many unemployed or underemployed sales people in China. As our business expands in China, we have experienced government scrutiny due to our international reputation as a direct selling company. 

The increase in revenue in China was somewhat offset by the decline in revenue in Taiwan. We believe that the SARS epidemic negatively impacted revenue in Taiwan and Hong Kong during the first half of 2003 . In addition, revenue in Taiwan and Hong Kong during the second, third, and fourth quarters of 2002  was positively impacted by distributor en- thusiasm surrounding our planned expansion of operations in China in 2003 . 

North America.  The following table sets forth revenue for the North America region and its principal markets: 

<img src='content_image/58475.jpg'>

The decline in revenue in the United States is principally a result of a $ 22 . 0  million revenue decline in Big Planet in 2003  compared to the prior year. This decline was due primarily to the sale of our professional employer organization and the restructuring of Big Planet telecommunication products, both of which transitions are part of our continued efforts to eliminate or modify low margin products. In addition, revenue in 2002  in the United States included $ 6 . 0  million of sales to foreign distributors during the third quarter of 2002  at the global distributor convention held in the United States, which did not recur in 2003 . 

Increasing distributor activity tied to the BioPhotonic Scanner program, a focus on signing up more consumers on monthly reorder programs, the introduction of new weight management products and implementation of distributor leader- ship incentives, however, resulted in 36 % growth in our Pharmanex revenue in the United States from $ 48 . 3  million in 2002  to $ 65 . 6  million in 2003 , excluding sales to foreign distributors at the 2002  global convention held in the United States. Nu Skin revenue held relatively constant in 2003  compared to 2002 , excluding sales to foreign distributors at the same 2002  global convention. Moreover, we experienced an 18 % increase in our 2003  executive distributors in the United States and a 20 % increase during 2003  of automatic delivery orders compared to 2002 . Early in 2003 , the FDA questioned the status of the BioPhotonic Scanner as a non-medical device. We believe the BioPhotonic Scanner can be marketed as a non-medical device, but the FDA has not responded yet to our request to classify the BioPhotonic Scanner as a non-medical device. In the event the FDA concludes that the BioPhotonic Scanner requires medical device clearance, this could delay or inhibit our ability to market the BioPhotonic Scanner. We intend to contest any conclusion by the FDA that the BioPho- tonic Scanner is a medical device. 

